RxDoctor Payments Data

Laura Larose

Nurse Practitioner · Santa Monica, CANPI 1538687462

Payments from drug & device makers

$13,548in general payments, 2019–2025

Across 121 payments — averaging $111.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • Pfizer$2K
  • Dova Pharmaceuticals$1K
  • AstraZeneca$1K
  • GSK$1K
  • Janssen Scientific Affairs, LLC$955
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$4,07030%
  • Speaking & faculty fees$3,20024%
  • Food & beverage$2,38118%
  • Education$2992%
  • Other$3,59827%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,548 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$6,134
Medicare patients
51
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LonsurfTrifluridine/Tipiracil Hcl31$324,641
RevlimidLenalidomide14$259,946
CalquenceAcalabrutinib Maleate17$242,433
EliquisApixaban103$83,997
XareltoRivaroxaban38$26,133
CreonLipase/Protease/Amylase19$16,189
Dexamethasone113$2,178
Acyclovir67$1,256
Sodium Chloride0.9 % Sodium Chloride21$961
Ondansetron Hcl51$758
Warfarin Sodium55$698
Prochlorperazine Maleate56$546
Lidocaine-PrilocaineLidocaine/Prilocaine42$459
Hydroxyurea13$420
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim70$400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$195$259,94614 claims
AstraZenecaCalquence$1,220$242,43317 claims
PfizerEliquis$1,842$83,997103 claims
Johnson & JohnsonXarelto$735$26,13338 claims
Lilly USA, LLCOlanzapine$169$16717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →